Pharsight

Mozobil generic

Mozobil is a patented drug owned by Genzyme. Its active ingredient is plerixafor, and it was first authorised for market use on 15th December, 2008 in solution;subcutaneous forms. The drug holds a total of 2 patents, both of which have now expired.

When will Mozobil generic be available?

As of now, all patents for Mozobil have expired. This means that generics of Mozobil could be released any time now. However, still, there's an important date to be noted i.e., 22nd July, 2023, which could possibly be the concrete date for the release of Mozobil generic.

Mozobil uses

Mozobil is used in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to the peripheral blood. This is done for collecting and subsequent autologous transplantation in patients with non-hodgkin's lymphoma & multiple myeloma.

Mozobil patent expiration

Mozobil has held two patents in total: US7897590 and US6987102, both titled as 'Methods to mobilize progenitor/stem cells'. Both these patents expired on 22nd July, 2023. Post this date, the generics of Mozobil could be released anywhere. Below are the details of the patents:

EPO Oppostions filed on Mozobil

Mozobil dosage

Want to ask something?